• +1-646-491-9876
    • +91-20-67278686

    Search

    Dyslipidemia - Pipeline Review, H1 2017

    Dyslipidemia - Pipeline Review, H1 2017

    • Report Code ID: RW0001709478
    • Category Pharmaceuticals
    • No. of Pages 280
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Dyslipidemia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

    Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 17, 19, 14, 4, 41 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 4 molecules, respectively.

    Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 6
    List of Figures 8
    Introduction 10
    Publisher Report Coverage 10
    Dyslipidemia - Overview 11
    Dyslipidemia - Therapeutics Development 12
    Pipeline Overview 12
    Pipeline by Companies 13
    Pipeline by Universities/Institutes 18
    Products under Development by Companies 19
    Products under Development by Universities/Institutes 25
    Dyslipidemia - Therapeutics Assessment 26
    Assessment by Target 26
    Assessment by Mechanism of Action 30
    Assessment by Route of Administration 34
    Assessment by Molecule Type 36
    Dyslipidemia - Companies Involved in Therapeutics Development 38
    Acasti Pharma Inc 38
    Akcea Therapeutics Inc 38
    Allergan Plc 39
    Amgen Inc 39
    Arisaph Pharmaceuticals Inc 40
    AstraZeneca Plc 40
    BASF SE 41
    BCWorld Pharm Co Ltd 41
    BioRestorative Therapies Inc 42
    Boryung Pharmaceutical Co Ltd 42
    Cadila Pharmaceuticals Ltd 43
    Cardax Inc 43
    Catabasis Pharmaceuticals Inc 44
    Celon Pharma SA 44
    Cerenis Therapeutics Holding SA 45
    Chong Kun Dang Pharmaceutical Corp 45
    CJ HealthCare Corp 46
    Connexios Life Sciences Pvt Ltd 46
    CymaBay Therapeutics Inc 47
    Daewoong Pharmaceutical Co Ltd 47
    Daiichi Sankyo Company Ltd 48
    Eli Lilly and Company 48
    Esperion Therapeutics Inc 49
    Gemphire Therapeutics Inc 49
    Gilead Sciences Inc 50
    GlaxoSmithKline Plc 50
    Golden Biotechnology Corp 51
    HanAll Biopharma Co Ltd 51
    Hanmi Pharmaceuticals Co Ltd 52
    Huons Co Ltd 52
    Hyundai Pharmaceutical Co Ltd 53
    Innovent Biologics Inc 53
    IPCA Laboratories Ltd 54
    Jeil Pharmaceutical Co Ltd 54
    Jenrin Discovery Inc 55
    JW Pharmaceutical Corp 55
    Kissei Pharmaceutical Co Ltd 56
    Kotobuki Pharmaceutical Co Ltd 56
    Kowa Company Ltd 57
    Kuhnil Pharmaceutical Co Ltd 57
    Kyorin Pharmaceutical Co Ltd 58
    Lipicard Technologies Ltd 58
    Lipigon Pharmaceuticals AB 59
    LipimetiX Development Inc 59
    Lotus Pharmaceutical Co Ltd 60
    Matinas BioPharma Holdings Inc 60
    Merck & Co Inc 61
    Nippon Chemiphar Co Ltd 61
    Omeros Corp 62
    Pfizer Inc 62
    Pharmena SA 63
    Protalix BioTherapeutics Inc 63
    Regeneron Pharmaceuticals Inc 64
    Samjin Pharmaceutical Co Ltd 64
    Sancilio & Company Inc 65
    Takeda Pharmaceutical Company Ltd 65
    Tasly Pharmaceutical Group Co Ltd 66
    Torrent Pharmaceuticals Ltd 66
    Yuhan Corp 67
    Zydus Cadila Healthcare Ltd 67
    Dyslipidemia - Drug Profiles 68
    (amlodipine besylate + fimasartan + rosuvastatin calcium) - Drug Profile 68
    (amlodipine besylate + olmesartan medoxomil) + rosuvastatin calcium - Drug Profile 69
    (amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 70
    (amlodipine besylate + rosuvastatin calcium) - Drug Profile 71
    (amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile 72
    (amlodipine maleate + rosuvastatin calcium + telmisartan) - Drug Profile 73
    (atorvastatin calcium + choline fenofibrate) - Drug Profile 74
    (atorvastatin calcium + hydroxychloroquine sulfate) - Drug Profile 75
    (atorvastatin calcium + metformin hydrochloride XR) - Drug Profile 76
    (atorvastatin calcium IR + losartan potassium DR) - Drug Profile 77
    (candesartan cilexetil + rosuvastatin calcium) - Drug Profile 78
    (metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 79
    (metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 80
    (nebivolol hydrochloride + rosuvastatin calcium) - Drug Profile 81
    (pitavastatin + valsartan) - Drug Profile 82
    4655-K09 - Drug Profile 83
    AC-261066 - Drug Profile 84
    AEM-28 - Drug Profile 85
    AEM-2802 - Drug Profile 87
    AEM-2814 - Drug Profile 88
    ALN-AC3 - Drug Profile 89
    ALN-ANG - Drug Profile 90
    AMG-899 - Drug Profile 91
    anacetrapib - Drug Profile 93
    Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia - Drug Profile 95
    antroquinonol - Drug Profile 96
    ARGX-116 - Drug Profile 98
    ARI-3037MO - Drug Profile 99
    bempedoic acid - Drug Profile 101
    bezafibrate SR - Drug Profile 113
    BioE-1115 - Drug Profile 115
    BKC-007 - Drug Profile 116
    BSN-272 - Drug Profile 117
    C-3 - Drug Profile 118
    CAT-2000 Series - Drug Profile 119
    CAT-2003 - Drug Profile 120
    CDR-267F018 - Drug Profile 123
    CDX-085 - Drug Profile 124
    centatin - Drug Profile 127
    CER-209 - Drug Profile 128
    CKD-519 - Drug Profile 129
    CNX-013B2 - Drug Profile 131
    DF-461 - Drug Profile 132
    Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile 133
    DS-9001 - Drug Profile 134
    DWJ-1330 - Drug Profile 136
    etanercept biosimilar - Drug Profile 137
    evinacumab - Drug Profile 139
    gemcabene calcium - Drug Profile 141
    GSK-2041706 - Drug Profile 145
    HCP-1105 - Drug Profile 146
    HOB-071 - Drug Profile 147
    HU-012 - Drug Profile 148
    IBI-306 - Drug Profile 149
    icosabutate - Drug Profile 150
    IMMH-007 - Drug Profile 152
    IONIS-ANGPTL3LRx - Drug Profile 153
    IONIS-APOCIIILRX - Drug Profile 155
    JD-2000 Series - Drug Profile 156
    JD-5000 Series - Drug Profile 157
    JD-5006 - Drug Profile 158
    JD-5037 - Drug Profile 159
    JD-6000 Series - Drug Profile 160
    JS-002 - Drug Profile 161
    K-312 - Drug Profile 162
    KI-1107 - Drug Profile 163
    KKM-1201 - Drug Profile 164
    KT-6971 - Drug Profile 165
    KTA-439 - Drug Profile 166
    leucine + niacin - Drug Profile 167
    liothyronine sodium - Drug Profile 168
    LP-071 - Drug Profile 169
    LT-5421 - Drug Profile 170
    LT-5423 - Drug Profile 171
    LTPO-3FA - Drug Profile 172
    LY-3202328 - Drug Profile 173
    MAT-9001 - Drug Profile 174
    metformin hydrochloride + rosuvastatin calcium - Drug Profile 176
    MN-002 - Drug Profile 177
    NC-2400 - Drug Profile 179
    ND-630 - Drug Profile 180
    ND-654 - Drug Profile 182
    NKPL-66 - Drug Profile 185
    Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 190
    omega-3-carboxylic acids - Drug Profile 191
    pemafibrate - Drug Profile 196
    peroxibrate - Drug Profile 199
    PF-06427878 - Drug Profile 200
    Protein for Dislipidemia, Obesity and Type 2 Diabetes - Drug Profile 201
    Recombinant ApoE4 for Dyslipidemia - Drug Profile 202
    REGN-1001 - Drug Profile 203
    saroglitazar - Drug Profile 204
    SC-401 - Drug Profile 207
    seladelpar - Drug Profile 208
    SJP-1603 - Drug Profile 212
    Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 213
    Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 214
    Small Molecule for Atherosclerosis and Hyperlipidemia - Drug Profile 215
    Small Molecule for Cardiovascular and Metabolic Diseases - Drug Profile 216
    Small Molecule for Hypertriglyceridaemia - Drug Profile 217
    Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 218
    Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 219
    Small Molecule to Agonize TR-Beta for Dyslipidemia - Drug Profile 220
    Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia - Drug Profile 221
    Small Molecule to Inhibit DGAT-2 for Dyslipidemia and Non-Alcoholic Steatohepatitis - Drug Profile 222
    Small Molecule to Inhibit HSL for Dyslipidemia - Drug Profile 223
    Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 224
    Small Molecules to Inhibit FABP1 for Hyperlipidemia and Fatty Liver Disease - Drug Profile 225
    Small Molecules to Target GPR146 for Metabolic Disorders - Drug Profile 226
    SPX-8522876 - Drug Profile 227
    Stem Cell Therapy for Hypertension, Hyperlipidemia, Obesity and Type 2 Diabetes - Drug Profile 228
    Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 230
    Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 231
    TRC-210258 - Drug Profile 232
    TRIA-662 - Drug Profile 233
    TSL-1516 - Drug Profile 235
    volanesorsen sodium - Drug Profile 236
    ZLN-005 - Drug Profile 243
    ZLN-024 - Drug Profile 244
    ZYH-7 - Drug Profile 245
    Dyslipidemia - Dormant Projects 246
    Dyslipidemia - Discontinued Products 255
    Dyslipidemia - Product Development Milestones 259
    Featured News & Press Releases 259
    Appendix 271
    Methodology 271
    Coverage 271
    Secondary Research 271
    Primary Research 271
    Expert Panel Validation 271
    Contact Us 271
    Disclaimer 272

    List of Tables

    Number of Products under Development for Dyslipidemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Dyslipidemia - Pipeline by Acasti Pharma Inc, H1 2017
    Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H1 2017
    Dyslipidemia - Pipeline by Allergan Plc, H1 2017
    Dyslipidemia - Pipeline by Amgen Inc, H1 2017
    Dyslipidemia - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017
    Dyslipidemia - Pipeline by AstraZeneca Plc, H1 2017
    Dyslipidemia - Pipeline by BASF SE, H1 2017
    Dyslipidemia - Pipeline by BCWorld Pharm Co Ltd, H1 2017
    Dyslipidemia - Pipeline by BioRestorative Therapies Inc, H1 2017
    Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd, H1 2017
    Dyslipidemia - Pipeline by Cardax Inc, H1 2017
    Dyslipidemia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2017
    Dyslipidemia - Pipeline by Celon Pharma SA, H1 2017
    Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
    Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
    Dyslipidemia - Pipeline by CJ HealthCare Corp, H1 2017
    Dyslipidemia - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017
    Dyslipidemia - Pipeline by CymaBay Therapeutics Inc, H1 2017
    Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Dyslipidemia - Pipeline by Eli Lilly and Company, H1 2017
    Dyslipidemia - Pipeline by Esperion Therapeutics Inc, H1 2017
    Dyslipidemia - Pipeline by Gemphire Therapeutics Inc, H1 2017
    Dyslipidemia - Pipeline by Gilead Sciences Inc, H1 2017
    Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H1 2017
    Dyslipidemia - Pipeline by Golden Biotechnology Corp, H1 2017
    Dyslipidemia - Pipeline by HanAll Biopharma Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Huons Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Innovent Biologics Inc, H1 2017
    Dyslipidemia - Pipeline by IPCA Laboratories Ltd, H1 2017
    Dyslipidemia - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Jenrin Discovery Inc, H1 2017
    Dyslipidemia - Pipeline by JW Pharmaceutical Corp, H1 2017
    Dyslipidemia - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Kowa Company Ltd, H1 2017
    Dyslipidemia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Lipicard Technologies Ltd, H1 2017
    Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB, H1 2017
    Dyslipidemia - Pipeline by LipimetiX Development Inc, H1 2017
    Dyslipidemia - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
    Dyslipidemia - Pipeline by Merck & Co Inc, H1 2017
    Dyslipidemia - Pipeline by Nippon Chemiphar Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Omeros Corp, H1 2017
    Dyslipidemia - Pipeline by Pfizer Inc, H1 2017
    Dyslipidemia - Pipeline by Pharmena SA, H1 2017
    Dyslipidemia - Pipeline by Protalix BioTherapeutics Inc, H1 2017
    Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Dyslipidemia - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Sancilio & Company Inc, H1 2017
    Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Dyslipidemia - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
    Dyslipidemia - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
    Dyslipidemia - Pipeline by Yuhan Corp, H1 2017
    Dyslipidemia - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Dyslipidemia - Dormant Projects, H1 2017
    Dyslipidemia - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Dyslipidemia - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Dyslipidemia - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Dyslipidemia - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Dyslipidemia - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Dyslipidemia - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Dyslipidemia - Dormant Projects, H1 2017 (Contd..7) , H1 2017
    Dyslipidemia - Dormant Projects, H1 2017 (Contd..8) , H1 2017
    Dyslipidemia - Discontinued Products, H1 2017
    Dyslipidemia - Discontinued Products, H1 2017 (Contd..1) , H1 2017
    Dyslipidemia - Discontinued Products, H1 2017 (Contd..2) , H1 2017
    Dyslipidemia - Discontinued Products, H1 2017 (Contd..3) , H1 2017

    List of Figures

    Number of Products under Development for Dyslipidemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Acasti Pharma Inc
    Akcea Therapeutics Inc
    Allergan Plc
    Amgen Inc
    Arisaph Pharmaceuticals Inc
    AstraZeneca Plc
    BASF SE
    BCWorld Pharm Co Ltd
    BioRestorative Therapies Inc
    Boryung Pharmaceutical Co Ltd
    Cadila Pharmaceuticals Ltd
    Cardax Inc
    Catabasis Pharmaceuticals Inc
    Celon Pharma SA
    Cerenis Therapeutics Holding SA
    Chong Kun Dang Pharmaceutical Corp
    CJ HealthCare Corp
    Connexios Life Sciences Pvt Ltd
    CymaBay Therapeutics Inc
    Daewoong Pharmaceutical Co Ltd
    Daiichi Sankyo Company Ltd
    Eli Lilly and Company
    Esperion Therapeutics Inc
    Gemphire Therapeutics Inc
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Golden Biotechnology Corp
    HanAll Biopharma Co Ltd
    Hanmi Pharmaceuticals Co Ltd
    Huons Co Ltd
    Hyundai Pharmaceutical Co Ltd
    Innovent Biologics Inc
    IPCA Laboratories Ltd
    Jeil Pharmaceutical Co Ltd
    Jenrin Discovery Inc
    JW Pharmaceutical Corp
    Kissei Pharmaceutical Co Ltd
    Kotobuki Pharmaceutical Co Ltd
    Kowa Company Ltd
    Kuhnil Pharmaceutical Co Ltd
    Kyorin Pharmaceutical Co Ltd
    Lipicard Technologies Ltd
    Lipigon Pharmaceuticals AB
    LipimetiX Development Inc
    Lotus Pharmaceutical Co Ltd
    Matinas BioPharma Holdings Inc
    Merck & Co Inc
    Nippon Chemiphar Co Ltd
    Omeros Corp
    Pfizer Inc
    Pharmena SA
    Protalix BioTherapeutics Inc
    Regeneron Pharmaceuticals Inc
    Samjin Pharmaceutical Co Ltd
    Sancilio & Company Inc
    Takeda Pharmaceutical Company Ltd
    Tasly Pharmaceutical Group Co Ltd
    Torrent Pharmaceuticals Ltd
    Yuhan Corp
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//dyslipidemia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//dyslipidemia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//dyslipidemia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments